Literature DB >> 15139512

Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.

Cristina Segura1, Eva Bandrés, Iñaki F Trocóniz, Jesús García-Foncillas, Onintza Sayar, Carmen Dios-Vieítez, Maria Jesús Renedo, María J Garrido.   

Abstract

PURPOSE: To evaluate the hematotoxicity of topotecan (TPT) in tumor-bearing rats by a pharmacokinetic/pharmacodynamic approach.
METHODS: DHD/K12-PROb cells were subcutaneously injected in syngenic BD-IX rats. Three weeks after implantation of cells, animals received saline or 6 mg/kg i.p. dose of TPT (group II). Thirty days later, group II was divided into groups IIA receiving a single administration of 6 mg/kg and IIB treated with 3 mg/kg for 2 consecutive days. Leukocytes, neutrophils, and mature lymphocytes were measured in peripheral blood every 48 h for 45 days after first drug administration. Pharmacokinetic characteristics of TPT were also explored.
RESULTS: Disposition of TPT in plasma was best described with a two-compartment model. A semiphysiological model discriminating between system-related and drug-effects parameters, such as the mean cell maturation or transition time (MTT) and the linear concentration-dependent inhibitory effects on cell proliferation (Slp), described adequately the time course of hematotoxicity. The estimates of MTT and Slp for the three cell populations ranged from 1.89 to 2.18 days and from 0.01 to 0.039 ml/ng, respectively.
CONCLUSION: The time course of the hematotoxicity induced after two cycles of chemotherapy with TPT in tumor-bearing rats could be described by a semiphysiological model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139512     DOI: 10.1023/b:pham.0000022402.00699.5c

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

Review 1.  Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer.

Authors:  Jaafar Bennouna; Jean-Yves Douillard
Journal:  Int J Clin Oncol       Date:  2002-08       Impact factor: 3.402

Review 2.  Irinotecan in the treatment of colorectal cancer: clinical overview.

Authors:  U Vanhoefer; A Harstrick; W Achterrath; S Cao; S Seeber; Y M Rustum
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Orthotopic implantation of colon carcinoma cells provides an experimental model in the rat that replicates the regional spreading pattern of human colorectal cancer.

Authors:  D García-Olmo; M García-Rivas; D C García-Olmo; M Atiénzar
Journal:  Cancer Lett       Date:  1998-10-23       Impact factor: 8.679

4.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Authors:  L E Friberg; A Freijs; M Sandström; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

Review 5.  Differentiation and proliferation of hematopoietic stem cells.

Authors:  M Ogawa
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

6.  Clinicopathological study of involvement of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor in non-lymphohematopoietic malignant tumors accompanied by leukocytosis.

Authors:  K Kojima; F Nakashima; A Boku; Y Muroishi; I Nakanishi; Y Oda
Journal:  Histol Histopathol       Date:  2002-10       Impact factor: 2.303

7.  Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

Authors:  Anna K Nowak; Bruce W S Robinson; Richard A Lake
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

8.  Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

Authors:  G J Creemers; C J Gerrits; J H Schellens; A S Planting; M E van der Burg; V M van Beurden; M de Boer-Dennert; M Harteveld; W Loos; I Hudson; G Stoter; J Verweij
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

Review 9.  Clinical pharmacokinetics of topotecan.

Authors:  V M Herben; W W ten Bokkel Huinink; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

10.  Blood transit and recirculation kinetics of lymphocyte subsets in normal rats.

Authors:  J Westermann; Z Puskas; R Pabst
Journal:  Scand J Immunol       Date:  1988-08       Impact factor: 3.487

View more
  6 in total

1.  A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.

Authors:  Angelica Linnea Quartino; Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2010-12-14       Impact factor: 3.850

2.  Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.

Authors:  Shinji Kobuchi; Yukako Ito; Toshiyuki Sakaeda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

3.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

4.  Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.

Authors:  Jessica D Sun; Qian Liu; Dharmendra Ahluwalia; Damien J Ferraro; Yan Wang; Don Jung; Mark D Matteucci; Charles P Hart
Journal:  Cancer Biol Ther       Date:  2016-01-28       Impact factor: 4.742

5.  A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells.

Authors:  Nieves Vélez de Mendizábal; Iván Martínez-Forero; María J Garrido; Eva Bandrés; Jesús García-Foncillas; Cristina Segura; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2010-01-26       Impact factor: 4.200

6.  Toxicogenomics profiling of bone marrow from rats treated with topotecan in combination with oxaliplatin: a mechanistic strategy to inform combination toxicity.

Authors:  Myrtle Davis; Jianying Li; Elaine Knight; Sandy R Eldridge; Kellye K Daniels; Pierre R Bushel
Journal:  Front Genet       Date:  2015-02-12       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.